EUCTR2008-006899-30-IT进行中（未招募）不适用
PHASE II STUDY OF 90Y-IBRITUMOMAB TIUXETAN AND FOTEMUSTINE ASSOCIATED WITH CYTARABINE ETOPOSIDE MELPHALAN AS CONDITIONING CHEMORADIOIMMUNOTHERAPY IN PATIENTS AFFECTED BY LYMPHOMA (HODGKIN AND NON-HODGKIN) CD20+ REFRACTORY/RELAPSED WITH MINIMAL RESIDUAL PERSISTANT DISEASE PRE-AUTOLOGOUS TRANSPLANT - Z-FEAM
ISTITUTI FISIOTERAPICI OSPITALIERI0 个研究点开始时间: 2008年12月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •PATIENTS <= 65 YEARS AFFECTED BY LYMPHOMA (HODGKIN AND NON-HODGKIN) CD20+ REFRACTORY/RELAPSED WITH MINIMAL RESIDUAL PERSISTANT DISEASE PRE-AUTOLOGOUS TRANSPLANT
- •KARNOFSKY PERFORMANCE STATUS >= 70
- •WRITTEN INFORMED CONSENT
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •SECOND CONCOMITANT NEOPLASM
- •HIV SEROPOSITIVITY
研究者
相似试验
进行中（未招募）
1 期
Phase II study of 90Y ibritumomab tiuxetan (Zevalin) in patients with untreated follicular non-Hodgkin's lymphoma. - ZEUSEUCTR2006-006808-11-ITAZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA
已完成
2 期
90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell LymphomaLymphoma, Large B-Cell, DiffuseNCT01157988Chonnam National University Hospital20
进行中（未招募）
1 期
Phase II Study of Fractionated 90Y Ibritumomab tiuxetan (ZevalinTM) as initial therapy of Follicular Lymphoma - FIZZ StudyFollicular lymphoma LLT Follicle centre lymphoma, follicular grade I, II, III PT Follicle centre lymphoma, follicular grade I, II, III MedDRA Version 9EUCTR2006-000598-31-GBChristie Hospital NHS Trust80
已完成
2 期
Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular LymphomaFollicular LymphomaNCT01446562Sunnybrook Health Sciences Centre34
招募中
1 期
Phase Ib/II Study of the Combination of Tucidinostat and Rituximab in Patients with Relapsed or Refractory B-cell Non-Hodgkin's LymphomaB-cell Non-Hodgkin's LymphomaJPRN-jRCT2041210129Hatake Kiyohiko71